These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 31524233)
1. Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. Liu B; Liu ZZ; Zhou ML; Lin JW; Chen XM; Li Z; Gao WB; Yu ZD; Liu T Mol Med Rep; 2019 Sep; 20(3):2823-2831. PubMed ID: 31524233 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies. Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584 [TBL] [Abstract][Full Text] [Related]
3. Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells. Chiawpanit C; Wathikthinnakorn M; Sawasdee N; Phanthaphol N; Sujjitjoon J; Junking M; Yamabhai M; Panaampon J; Yenchitsomanus PT; Panya A Int Immunopharmacol; 2024 Jul; 136():112273. PubMed ID: 38810311 [TBL] [Abstract][Full Text] [Related]
4. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma. Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430 [TBL] [Abstract][Full Text] [Related]
5. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014 [TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer. Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795 [TBL] [Abstract][Full Text] [Related]
7. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma. Kang CH; Kim Y; Lee SM; Choi SU; Park CH Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386 [TBL] [Abstract][Full Text] [Related]
8. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173 [TBL] [Abstract][Full Text] [Related]
9. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer. Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A Cells; 2020 Jun; 9(6):. PubMed ID: 32498368 [TBL] [Abstract][Full Text] [Related]
10. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma. Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108 [TBL] [Abstract][Full Text] [Related]